Home » Posts tagged with » USA
Lilly to build $470m pharma manufacturing plant in North Carolina

Lilly to build $470m pharma manufacturing plant in North Carolina

US pharma giant Eli Lilly and Company (Lilly) will build a new pharma manufacturing plant in North Carolina with an investment of more than $470 million for producing injectable products and delivery devices. The new Lilly pharma manufacturing facility will be built in Research Triangle Park, and will generate over 460 new jobs in Durham. […]

Todos Medical to acquire in vitro diagnostics company Provista Diagnostics

Todos Medical acquisition of Provista Diagnostics : Israel-based Todos Medical signed an exclusive option agreement to acquire Provista Diagnostics,  an in vitro diagnostics company having a CLIA/CAP certified lab in Alpharetta, Georgia. Financial terms of the possible deal have not been disclosed. Todos Medical is an in-vitro diagnostics company engaged in developing blood tests for […]

Continue reading …
TenNor Therapeutics gets FDA orphan drug status for TNP-2092 in prosthetic joint infections

TenNor Therapeutics has secured orphan drug designation from the US Food and Drug Administration (FDA) for its multitargeting drug conjugate TNP-2092 for the treatment of prosthetic joint infections. According to the Chinese biopharma company, biofilm infections associated with prosthetic joints, central venous catheters, artificial heart valves, and other medical devices has become a huge challenge. […]

Continue reading …
BioTheryX begins BTX-A51 phase 1 trial in AML and myelodysplastic syndrome

BTX-A51 phase 1 trial : US biotech company BioTheryX has initiated patient dosing in its first clinical program of its small molecule BTX-A51 in patients having relapsed/refractory acute myeloid leukemia (AML), and also in high-risk myelodysplastic syndrome patients. The phase 1 clinical trial of BTX-A51 will assess the safety, pharmacokinetics, and tolerability of the oral […]

Continue reading …
Arena Pharmaceuticals’ APD418 gets FDA fast track status in decompensated heart failure

Arena Pharmaceuticals has secured that fast track designation for its drug candidate APD418 from the US Food and Drug Administration (FDA) for the treatment of decompensated heart failure (DHF). APD418 is a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope. According to the San Diego-based biopharma company, APD418 is a selective antagonist that has been designed […]

Continue reading …
Cerevel launches phase 3 Parkinson’s disease clinical trials for tavapadon

Parkinson’s disease clinical trials : Cerevel Therapeutics, a US biopharma company, has initiated a phase 3 clinical trial program for evaluating tavapadon in Parkinson’s disease patients, as per the latest clinical trial news. Tavapadon is being developed as an orally-bioavailable, selective partial agonist of the dopamine D1 and D5 receptors, and is being assessed for […]

Continue reading …
NeuroBo, Gemphire merger wrapped up to form neurodegenerative disease company

NeuroBo Pharmaceuticals,  a Boston-based clinical-stage pharma company, has wrapped up its previously announced merger with Gemphire Therapeutics, a Michigan-based clinical-stage biopharma company focused on developing therapies for dyslipidemia and nonalcoholic fatty liver disease (NASH). The new combined company will be called NeuroBo Pharmaceuticals, which will focus on advancing a clinical-stage pipeline targeting neurodegenerative diseases. NeuroBo, […]

Continue reading …
Taro recalls lot of Lamotrigine tablets in US due to contamination

Taro Pharmaceuticals U.S.A. has issued to recall of a lot of Lamotrigine 100 mg tablets owing to cross-contamination with a trace of another drug substance – Enalapril Maleate. Lamotrigine is indicated for the treatment of epilepsy and bipolar disorders. The US pharmaceutical manufacturer is recalling Lot # 331771, which has an expiration date June 2021 […]

Continue reading …
PACT Pharma raises $75m to develop neoTCR-T cell therapies for solid tumors

PACT Pharma, a California-based clinical stage company, which is focused on developing fully personalized neoTCR-T cell therapies for solid tumors, has raised $75 million in a Series C financing round. The funding round was led by Vida Ventures, a life science venture firm, with participation from the current investors of PACT Pharma. The clinical stage […]

Continue reading …
MiraDx to enroll patients for non-tumor based microRNA clinical trial

MicroRNA clinical trial : MiraDx, a Los Angeles-based molecular genetics company, has initiated patient enrollment in collaboration with UCLA for the non-tumor based microRNA biomarker-driven clinical trial for KRAS-variant positive HPV-positive head and neck cancer patients (HNSCC). The clinical trial will randomly group 70 patients to receive the current standard of care (radiation plus cisplatin) […]

Continue reading …
Page 1 of 30123Next ›Last »